S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$166.42
+1.1%
$175.44
$130.96
$182.89
$294.67B0.585.64 million shs5.53 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$726.31
-2.6%
$763.96
$369.76
$800.78
$708.78B0.342.20 million shs3.49 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$122.70
0.0%
$126.39
$75.56
$138.28
$550.84B0.413.26 million shs5.18 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.99
+2.4%
$27.11
$25.23
$40.37
$143.77B0.6134.24 million shs38.35 million shs
Roche Holding AG stock logo
RHHBY
Roche
$30.41
+1.2%
$32.07
$29.95
$40.48
N/A0.393.16 million shs11.81 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.07%+2.53%-5.59%+1.00%+3.23%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.63%-3.37%-6.02%+15.55%+96.05%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.05%-1.46%-5.88%+14.72%+197.40%
Pfizer Inc. stock logo
PFE
Pfizer
+2.38%+0.46%-6.21%-8.10%-35.41%
Roche Holding AG stock logo
RHHBY
Roche
+1.20%-0.59%-6.77%-13.95%-20.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9148 of 5 stars
2.45.04.23.92.92.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8287 of 5 stars
2.44.02.54.02.52.53.1
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.804 of 5 stars
1.45.02.50.02.50.03.1
Pfizer Inc. stock logo
PFE
Pfizer
4.991 of 5 stars
3.25.04.24.82.51.73.1
Roche Holding AG stock logo
RHHBY
Roche
2.5639 of 5 stars
3.02.01.70.02.50.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.436.61% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.050.24% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.75
Moderate Buy$133.608.88% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.35
Hold$36.8841.88% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.00
Hold$40.0031.54% Upside

Current Analyst Ratings

Latest NVO, ABBV, RHHBY, LLY, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/12/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$163.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/1/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/27/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $195.00
(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.42$16.02 per share10.39$5.78 per share28.79
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.22$7.38 per share98.44$11.44 per share63.49
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$33.71B16.33$2.97 per share41.36$3.45 per share35.57
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.52$3.04 per share8.54$15.81 per share1.64
Roche Holding AG stock logo
RHHBY
Roche
$65.37BN/A$3.14 per share9.68$4.91 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7360.9613.712.118.95%162.28%14.62%4/26/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80125.2339.281.6415.36%51.22%9.94%4/30/2024 (Confirmed)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$12.15B$2.7145.3630.002.0836.03%90.36%29.18%5/2/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3672.199.381.153.62%10.88%4.91%5/1/2024 (Confirmed)
Roche Holding AG stock logo
RHHBY
Roche
$12.81BN/A0.0011.394.38N/AN/AN/AN/A

Latest NVO, ABBV, RHHBY, LLY, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/26/2024N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20N/A-$2.20N/AN/AN/A  
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
1/31/2024Q4 2023
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.66$0.71+$0.05$0.71$9.14 billion$9.51 billion
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.73%+7.84%227.11%52 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.72%+15.15%89.66%10 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.331.08%+16.52%49.17%1 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.46%+2.57%466.67%15 Years
Roche Holding AG stock logo
RHHBY
Roche
$0.882.89%N/AN/AN/A

Latest NVO, ABBV, RHHBY, LLY, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
1/31/2024
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Semi-Annual$0.66400.9%3/22/20243/25/20244/2/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.19
0.82
0.64
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69
Roche Holding AG stock logo
RHHBY
Roche
0.75
1.35
1.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
63,3704.49 billion4.48 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,605N/AN/ANot Optionable

RHHBY, PFE, ABBV, NVO, and LLY Headlines

SourceHeadline
Pharma Stock Roundup: JNJs Q1 Results, LLY, ABBV, RHHBYs Successful Study DataPharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
msn.com - April 19 at 3:11 PM
Roche (RHHBY) Alecensa Wins FDA Nod for Label ExpansionRoche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
zacks.com - April 19 at 11:16 AM
F. Hoffmann-La Roche Ltd: FDA approves Roches Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerF. Hoffmann-La Roche Ltd: FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finanznachrichten.de - April 19 at 3:29 AM
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finance.yahoo.com - April 19 at 3:29 AM
Roche Announces FDA Approval For AlecensaRoche Announces FDA Approval For Alecensa
markets.businessinsider.com - April 19 at 3:29 AM
FDA approves Roches Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerFDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
globenewswire.com - April 19 at 1:00 AM
FDA Approves Genentechs Alecensa For ALK-positive Early-Stage Lung CancerFDA Approves Genentech's Alecensa For ALK-positive Early-Stage Lung Cancer
markets.businessinsider.com - April 18 at 10:08 PM
FDA Approves Genentechs Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung CancerFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
businesswire.com - April 18 at 4:35 PM
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSGenentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
finance.yahoo.com - April 17 at 10:38 AM
Celebration Obstetrics & Gynecology Now Accepting Partners Direct Health InsuranceCelebration Obstetrics & Gynecology Now Accepting Partner's Direct Health Insurance
finance.yahoo.com - April 16 at 1:44 PM
Roches Lymphoma Drug With Chemo Extends Survival In Pretreated PatientsRoche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
msn.com - April 15 at 3:19 PM
Roches (RHHBY) Combination Therapy Meets Goal in Lymphoma StudyRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
zacks.com - April 15 at 8:36 AM
Genentechs Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO StudyGenentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
businesswire.com - April 15 at 1:10 AM
[Ad hoc announcement pursuant to Art. 53 LR] Roches Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
globenewswire.com - April 15 at 1:00 AM
Guru Fundamental Report for RHHBYGuru Fundamental Report for RHHBY
nasdaq.com - April 13 at 12:02 AM
Why Roche Holdings Stock Popped TodayWhy Roche Holdings Stock Popped Today
fool.com - April 11 at 6:33 PM
F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimers disease diagnosisF. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
finanznachrichten.de - April 11 at 9:52 AM
Roches Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimers DetectionRoche's Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimer's Detection
markets.businessinsider.com - April 11 at 9:52 AM
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimers disease diagnosisRoche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
globenewswire.com - April 11 at 1:00 AM
Roche Gets CE Mark For First Companion Diagnostic To Identify HER2-low Metastatic Breast CancerRoche Gets CE Mark For First Companion Diagnostic To Identify HER2-low Metastatic Breast Cancer
markets.businessinsider.com - April 10 at 9:06 AM
Roche companion diagnostic test wins CE Mark to identify metastatic breast cancer patientsRoche companion diagnostic test wins CE Mark to identify metastatic breast cancer patients
msn.com - April 10 at 9:06 AM
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTURoche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
prnewswire.com - April 10 at 1:00 AM
Meet Europes Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
barrons.com - April 9 at 11:42 AM
Veracode Embarks on a New Chapter with Appointment of Brian Roche as Chief Executive OfficerVeracode Embarks on a New Chapter with Appointment of Brian Roche as Chief Executive Officer
businesswire.com - April 3 at 12:36 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Novo Nordisk A/S logo

Novo Nordisk A/S

NYSE:NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Roche logo

Roche

OTCMKTS:RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.